The dopamine transporter (DAT) has been a primary target for cocaine abuse/addiction medication discovery. However predicted addiction liability and limited clinical evaluation has provided a formidable challenge for development of these agents for human use. The unique and atypical pharmacological profile of the benztropine (BZT) class of dopamine uptake inhibitors, in preclinical models of cocaine effects and abuse, has encouraged further development of these agents. Moreover, in vivo studies have challenged the original DAT hypothesis and demonstrated that DAT occupancy and subsequent increases in dopamine produced by BZT analogues are significantly delayed and long lasting, as compared to cocaine. These important and distinctive elements are critical to the lack of abuse liability among BZT analogues, and improve their potential for development as treatments for cocaine abuse and possibly other neuropsychiatric disorders. © 2009 Springer Berlin Heidelberg.
CITATION STYLE
Hauck Newman, A., & Katz, J. L. (2009). Atypical dopamine uptake inhibitors that provide clues about cocaine’s mechanism at the dopamine transporter. Topics in Medicinal Chemistry. https://doi.org/10.1007/7355_2008_027
Mendeley helps you to discover research relevant for your work.